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CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic
deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We
followed 13 patients (age range 1–27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione
and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66–148 mg/kg/day in divided doses, and the term
examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-
measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary
exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N=10)
was 5.8 percentage points (pb0.0001), average weight percentile (N=13) increased 8.6 points (pb0.001), BMI percentile (N=11) improved on
average 1.22 points (pb0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile.
Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (pb0.03) with sputum cultures of Pseudomonas aeruginosa becoming
negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use
of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in
bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.
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There has been increasing interest in the role of glutathione
in the pathophysiology of cystic fibrosis. Since the discovery
that the CFTR channel was the major mechanism of GSH efflux
into the extracellular milieu of the lung from lung epithelial cells
and that this efflux was severely compromised in cystic fibrosis
(CF) [1–6], resulting in glutathione system dysfunction and
systemic deficiency of reduced glutathione (GSH) in CF, re-
searchers have begun to explore what role glutathione system
dysfunction plays in cystic fibrosis disease. Not only have in⁎ Corresponding author.
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doi:10.1016/j.jcf.2008.03.006vitro studies proven useful in the development of new hy-
potheses in this regard [7–17], but several clinical trials of GSH
or GSH precursors such as NAC have resulted in improvement
in clinically-relevant markers in CF patients [18–23].
2. Methods and cases
We followed 13 CF patients (age range 1–27 years; 7 male;
11 Italian patients (cases 1–11) and 2 American patients (cases
12–13)) with cystic fibrosis who were using a regimen of
reduced glutathione (GSH), including oral glutathione and in-
haled buffered glutathione, in an uncontrolled observational
study. No patient had used GSH prior to this study. These
patient histories were selected due to the recording of clinical
markers at the temporal intervals needed for comparison, asd by Elsevier B.V. All rights reserved.
Table 1
Dosing regimen for Italian (#1–11) and American (#12–13) patients
Italian patients American patients
Nebulizer Pari e-Flow Pari LC_Star or LC-Plus
Dosage 40 mg/kg/day by mouth, and
1800 mg/day by inhalation
66 mg/kg/day divided into




45 days of incrementally
increasing dose to full dose,
beginning with 30 mg bid to
900 mg bid for inhalation.
45 days of incrementally
increasing dose to full dose,
beginning with one-quarter
of the full dose
Oral GSH
source
GSH Caps and GSH-Curc Caps
(Theranaturals)





TAD (Italy) diluted in 4 L of
NAHCO3
−, 1 mEq/L to obtain pH




3.75 L sterile water to
obtain pH of 5.2 with
osmolarity of 469 mM/L
ORa
Reduced L-Glutathione Plus Sodium
Bicarbonate (Theranaturals)
diluted in 3.75 L sterile water
to obtain pH of 5.2 with
osmolarity of 469 mM/L
a Only one formulation of inhaled GSH was used with each Italian patient;
patient preference determined source.
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initiation of the GSH regimen.
Patients did not modify any of their prescribed CF thera-
peutic regimen, but merely added GSH to that regimen. Patients
requested to take GSH, having individually assessed this
treatment. The two physicians involved asked to observe cli-
nical markers of these patients, which request was fulfilled in
most cases. All cases used a combination of oral and inhaled
glutathione, as outlined in Table 1. Only pharmaceutical grade
GSH was used by the patients, and inhaled glutathione was
buffered to be of relatively neutral pH.
All thirteen patients had clinical markers assessed threemonths
before baseline, at baseline, and 5.5 months after baseline. ThreeTable 2A
Patient characteristics and clinical markers at 3 months before baseline, baseline, an
Case #, gender,
age (years)
Mutations FEV1 (% predicted) Weight (k
T−3 T0 T5.5 T−3
1, M, 8 DF508/DF508 58 56 64 22
2, F, 11 DF508/? 65 64 71 28.5
3, F, 19 DF508/G1244E 47 48 55 43
4, M, 5 DF508/R347P NA NA NA 17
5, M, 24 W1282G/G542X 60 58 70 51
6, F, 14 3659delC/? 70 71 72 42
7, F, 8 DF508/DF508 66 66 69 21
8, F, 7 Y1182X/G1244E 73 72 75 21
9, M, 27 DF508/2183delAA 38 38 44 53
10, M, 22 2183delAA/? 24 25 29 57
11, M, 15 DF508/R347H 42 44 51 50.5
12, M, 1 NA NA NA NA 10
13, F, 1 DF508/DF508 NA NA NA 7.5
NA — data not available.
T−3 — 3 months prior to baseline; T0 — baseline; T5.5 — 5.5 months after baselin
a Bacteria codes: SA = Staphylococcus aureus, PA = Pseudomonas aeruginos
Burkholderia cepacia.
b Chronic colonization with PA according to antibody status (Mancini–Heremanpatients had one or more missing indicators. All patients except
case 4 were pancreatic insufficient. Patient characteristics at
3 months before baseline, baseline, and 5.5 months after baseline
are provided in Table 2A; additional patient characteristics at
baseline and 5.5 months post-baseline are provided in Table 2B.
For patients #1–11, data on these clinical markers were available
three months prior to baseline; for patients #12–13, weight three
months prior to baseline was available. These clinical markers
were quite stable during this three month period. For example, the
change in FEV1 predicted ranged from −2% to 2% with an
average of −0.1%; the change in weight (kg) ranged from −0.5 to
0.5 kg with an average of −0.01 kg; and 8 patients had no change
in bacteria cultured in their sputum while 3 patients had one
additional bacteria at baseline. Therefore, the changes observed
over the 5.5 month study period do not appear to be part of any
trend toward improvement that started prior to GSH use.
3. Side effects
In three cases, mild side effects were noted. In Case 2, a
slight fever appeared on days 33–35, which spontaneously
disappeared without intervention. In Case 7, chest tightness was
felt on days 15–16, but disappeared without intervention. In
Case 11, diarrhea appeared on days 3–5, which resolved with-
out intervention. ALT measurements at baseline and 5.5 months
after baseline were collected for patients #1–11 to assess change
in liver function (Table 2B). The average change in ALT was
−3.72 IU/L (range 9 to −20), suggesting no hepatotoxic effects
from this regimen.
4. Results
Clinical markers for the individual patients measured
5.5 months after the GSH regimen began are shown in Table




(type of bacteria) a
T0 T5.5 T−3 T0 T5.5 T−3 T0 T5.5
22 24 17 13 31 SA,PAb SA,PAb SA
28 30 9 5 6 PA PA none
43 48 3 3 9 PA b PAb PA
17.5 19 33 33 40 SA SA none
51.5 57 3 3 7 BC BC BC
42 49 20 17 41 none SA none
20.5 23 12 6 14 SA SA,H none
20.5 21.5 35 23 21 none none none
53 58.5 3 3 10 PA b PAb SA
57 60.5 7 7 15 AX AX AX
50 54 30 24 32 PA SA,PA none
10 12 9 5 25 NA NA NA
8 9.5 0 0 3 NA NA NA
e.
a, H = Haemophilus influenzae type b., AX = Alcaligenes xylosidans, B =
s Radial Immunodiffusion assay).
Table 2B
Patient characteristics and clinical markers at baseline and 5.5 months after baseline





T0 T5.5 T0 T5.5 T0 T5.5
1, M, 8 DF508/DF508 14.1 14.6 2 0 22 24
2, F, 11 DF508/? 15.1 15.3 1 0 36 30
3, F, 19 DF508/G1244E 16.3 18.3 0 0 9 18
4, M, 5 DF508/R347P 14.7 15.4 0 1 11 11
5, M, 24 W1282G/G542X 17.8 19.7 1 0 16 20
6, F, 14 3659delC/? 16.6 19.3 0 0 22 22
7, F, 8 DF508/DF508 14.0 15.0 2 1 34 14
8, F, 7 Y1182X/G1244E 15.5 15.7 0 0 28 20
9, M, 27 DF508/2183delAA 18.1 20.0 3 1 48 31
10, M, 22 2183delAA/? 18.8 20.0 2 0 35 22
11, M, 15 DF508/R347H 17.5 18.7 1 1 10 18
12, M, 1 NA NA NA NA NA NA NA
13, F, 1 DF508/DF508 NA NA NA NA NA NA
NA — data not available.
T−3 — 3 months prior to baseline; T0 — baseline; T5.5 — 5.5 months after baseline.
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clinical parameters over the 5.5 month period of initiation of the
GSH regimen (Table 3).
5. Discussion
Though this observational study was uncontrolled, and there-
fore alternative explanations for the observed results are possible,
the results are intriguing. Over a 5.5 month period, average lung
function and weight parameters increased significantly, and num-
ber of bacteria cultures declined significantly.
From previous studies [18,22,23], we knew that inhaled
buffered GSH would elevate blood and ELF levels of GSH and
potentially increase lung function. These results corroborate
previously published findings that improved lung function is
associated with use of a GSH regimen in CF. Because these
previous studies focused on lung function parameters, clinical
indicators concerning the growth failure typical of pancreatic
insufficient CF patients were not examined in detail. In fact,
there was some reason to believe that oral glutathione would be
of little use in the treatment of CF patients [7]. Nevertheless,
these results show that significant weight gain is also associated
with use of this GSH regimen. Given recent research findingsTable 3
Change in clinical markers over 5.5 months on a GSH regimen
Clinical marker Baseline mean (SD) Post-mean (SD) D
FEV1, % predicted (N=10) 54.2 (15.3) 60 (14.9) 5
Weight (%) (N=13) 10.9 (10.3) 19.5 (13.1) 8
BMI (%) (N=11) 16.2 (1.7) 17.5 (2.2) 1
Clinical marker Baseline total #
Positive sputum cultures (N=11) 13
PA positive sputum cultures (N=11) 5
Exacerbations (N=11) 12
a Paired t-test.
b Sign test.showing a strong, significant, even predictive relationship
between weight and lung function in CF [25–30], the
significant weight gain observed in this 5.5 month study is of
special note. While the U.S. Food and Drug Administration has
recently asserted, “Literature reports clearly describe that orally
administered glutathione is well absorbed” [24], the mechanism
of oral uptake particularly requires further elucidation, espe-
cially in the case of CF patients whose glutathione system is
abnormal.
The number of sputum cultures positive for all types of
bacteria significantly declined over the study period. It is par-
ticularly interesting that 4 of the 5 cases that were originally
positive for Pseudomonas aeruginosa (PA) were negative for
PA 5.5 months later, including two of the three patients chro-
nically infected with PA. Recent research has demonstrated that
GSH in the ELF is specifically elevated through the CFTR
channel in reaction to infection with P. aeruginosa, and assists
in clearing that infection in normal organisms [4]. There was
also a marked decrease in number of pulmonary exacerbations
in this study, although a comparison is somewhat problematic
given the slightly longer observation period at baseline
(6 months prior to baseline versus 5.5 months study period).
Additional research is required to determine if a GSH regimenifference (post-base) mean (SD) 95% CI of difference p-value
.8 (3.2) (3.5, 8.1) pb0.0001 a
.6 (7.6) (4.0, 13.2) pb0.001 a
.2 (0.8) (0.7, 1.8) pb0.001 a
Post-total # Difference (post-base) p-value
5 6 declined pb0.03 b
5 no change
0 increased
1 −4 No test done
4 −8 No test done
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infection in the consequences of CFTR dysfunction.
It should be noted that an FDA-approved oral formulation
(Cachexon) is available in the United States, and two parenteral
formulations (TAD, Ridutox) are approved in Italy. Also, GSH
has been shown to be anti-genotoxic, anti-mutagenic, anti-
carcinogenic, and anti-toxic with no known adverse side effects
reported in the literature [31]. In this small observational study,
we could detect no hepatotoxic effects, as measured by pre- and
post-ALT levels.
This is not a call to encourage CF patients to begin treating
themselves with GSH, but rather a call to researchers and
clinicians to examine this therapeutic approach in a more
rigorous fashion. Such an examination for inhaled GSH is
already underway in Munich, Germany (PI: Matthias Griese),
with a randomized, placebo-controlled trial of 24 week duration
[32]. If a GSH regimen does ameliorate a number of important
CF clinical markers, larger randomized, controlled studies of
GSH augmentation in CF patients should be undertaken in as
expeditious a manner as possible.
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